Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Avnet commemorates its 50th Anniversary on the New York Stock Exchange

December 21, 2010 10:46 am | by Avnet | News | Comments

Avnet commemorated its 50th anniversary as a publicly traded company on the New York Stock Exchange (NYSE) by ringing the Closing Bell on Wednesday, December 15, 2010.

Mesa Labs buys Apex biological indicators business

December 21, 2010 10:45 am | News | Comments

Mesa Laboratories Inc. said Tuesday it acquired the biological indicators business of Apex Laboratories Inc. Terms of the deal were not disclosed.The Lakewood, Colo., company, which makes instruments and disposable products for healthcare and industrial applications, expects the deal to...

TTI, Inc. Launches Interactive Holiday Trivia Contest

December 21, 2010 10:34 am | by TTI, Inc. | News | Comments

It's the holiday season and to celebrate TTI, Inc. is inviting its customers, suppliers and electronics industry employees to play its new, on-line holiday trivia game launched this week that features The Specialist, the new company spokesperson recently selected from The Big Job Campaign.

Advertisement

ISSYS awarded two grants for Its wireless, batteryless implants and drug infusion medical products under the therapeutic discovery project

December 21, 2010 10:32 am | by I-Micronews | News | Comments

Integrated Sensing Systems, Inc. (ISSYS) announces that it has received two federal grants to aid in the support of its wireless implantable pressure sensors for the chronic treatment of congestive heart failure, as well as its drug infusion flow sensing technology for much safer drug...

Premarket Approval (PMA) Summary Review Memos for 180-Day Design Changes

December 21, 2010 9:36 am | by U.S. Food & Drug Administration | News | Comments

A 180-day supplement is a request for a significant change in components, materials, design, specification, software, color additive, and labeling to an approved premarket application or premarket report.

Fresenius Kabi LLC, Red Blood Cell (RBC) Exchange Sets used on AS104 Blood Cell Separation Devices: Class I Recall

December 21, 2010 9:30 am | by U.S. Food & Drug Administration | News | Comments

Use of the recalled product has led to removal of greater amounts of red blood cells than intended, resulting in hemodilution.

TOPICS:

Analyst: Nursing home owners to get Medicare boost

December 21, 2010 8:45 am | by The Associated Press | News | Comments

Nursing home owners and operators likely will get a boost from changes in Medicare's payment system next year, an analyst said Tuesday.Despite the run-up in shares of real estate investment trusts that focus on senior care, Morgan Keegan analyst Robert Mains said the sector still will post...

Insurer rate hikes to face fresh federal scrutiny

December 21, 2010 7:45 am | by TOM MURPHY - AP Business Writer - Associated Press | News | Comments

Health insurers will have to justify some rate hikes starting next year under a proposed federal rule that raises scrutiny for individual and small group policies that have slapped many consumers with soaring premiums.The Department of Health and Human Services said Tuesday it will require rate...

Advertisement

Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences

December 21, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /- Based on its recent analysis of the surface functionalization technologies market, Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with the 2010 Enabling Technology of the Year Award for Surface Functionalization...

TOPICS:

On Average, 55 Percent of Surveyed U.S. Asthma Patients Say They Are Likely to Request a Switch to a Drug With Efficacy Comparable to Their Current Medication but Which is Dos...

December 21, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 21, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an average of 55 percent of surveyed asthma patients in the U.S. report that they are likely or very likely to request a...

TOPICS:

Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis

December 21, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

DURHAM, N.C., Dec. 21, 2010 /- bioMerieux, a world leader in the field of in vitro diagnostics, announced the results of a survey demonstrating that most critical care nurses are unaware of a simple diagnostic test that may dramatically improve outcomes for sepsis patients. The survey,...

TOPICS:

Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group

December 21, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

DALLAS, Dec. 21, 2010 /- Generational Equity, a leading advisor to privately held and family-owned businesses for mergers, acquisitions, strategic growth initiatives, business valuation and exit planning announced the acquisition of its client, B-Pharm, Inc. dba Remedies Pharmacy,...

TOPICS:

Cambridge Heart takes in $2.9M

December 21, 2010 6:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Cambridge Heart Inc., the Tewksbury-based developer of diagnostic heart tests for cardiac disease, has raised $2.9 million in a private placement, the company reported today.

PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis

December 21, 2010 5:30 am | by Bio-Medicine.Org | News | Comments

SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo:...

TOPICS:

Federal Register: Meetings: Advisory Committees; Tentative Schedule for 2011

December 21, 2010 4:34 am | by U.S. Food & Drug Administration | News | Comments

The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2011.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading